Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
Jun 15 ABBV ALS therapy market seen increasing to nearly $1.3B by 2029
Jun 15 VRTX 3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Jun 14 VRTX Vertex Pharmaceuticals Incorporated (VRTX): A Promising Feminist Stock To Buy?
Jun 14 ABBV AbbVie urges shareholders to reject mini-tender offer
Jun 14 ABBV AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
Jun 14 VRTX Vertex says Casgevy benefit extends to nearly five years in sickle cell disease
Jun 14 ABBV Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Jun 14 ABBV AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Jun 14 RGLS Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
Jun 14 ABBV AbbVie joins in latest gastrointestinal drug chase
Jun 14 ABBV AbbVie and FutureGen link on inflammatory bowel disease
Jun 14 VRTX Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
Jun 13 BNTC Piper Sandler starts Benitec at overweight, cites BB-301 opportunity
Jun 13 ABBV Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends
Jun 13 ABBV AbbVie inks licensing pact for bowel disorder therapy
Jun 13 ABBV AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
Jun 12 ABBV AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Jun 12 VRTX Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
Jun 12 ABBV Cerevel Therapeutics gains after AbbVie says making good progress with FTC
Jun 12 VRTX 2 Healthcare Stocks to Buy Hand Over Fist in June
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags